Screener
Aurinia Pharmaceuticals AUPH Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Aurinia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Aurinia Pharmaceuticals’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 8:16 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001600620-26-000062
FAQ
- What is Aurinia Pharmaceuticals's total liabilities?
- Aurinia Pharmaceuticals (AUPH) reported total liabilities of $177.4M in Q2 2026.
- How has Aurinia Pharmaceuticals's total liabilities changed year-over-year?
- Aurinia Pharmaceuticals's total liabilities increased by 6.1% year-over-year, from $167.26M to $177.4M.
- What is the long-term trend for Aurinia Pharmaceuticals's total liabilities?
- Over 5 years (2020 to 2025), Aurinia Pharmaceuticals's total liabilities has grown at a 24.9% compound annual growth rate (CAGR), from $55.91M to $170.26M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Aurinia Pharmaceuticals's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude